Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN LACTOBIONATE versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN LACTOBIONATE versus ZMAX.
ERYTHROMYCIN LACTOBIONATE vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin lactobionate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation of peptides. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
1-4 g/day IV divided every 6 hours; maximum 4 g/day. Infuse over 20-60 minutes.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
Terminal elimination half-life: 1.4-2.0 hours in adults with normal renal function. In patients with anuria, half-life may be prolonged up to 4.8-6.0 hours.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily biliary excretion (80-90% as unchanged drug and metabolites); renal excretion accounts for 10-15% of the dose. Fecal elimination is minimal (<5%).
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic